Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting enzymes to cancers--new developments.

K D Bagshawe1, P J Burke, R J Knox

  • 1Enzacta Ltd, Building 115, Porton Science Park, Salisbury, Wiltshire, SP4 0JQ, UK.

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial.

Journal of the Royal College of Physicians of London·2019
Same author

The management of high-risk gestational trophoblastic tumours (GTT).

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2018
Same author

Radioimmunoassays [abridged].

Proceedings of the Royal Society of Medicine·2010
Same author

Chemotherapy in breast cancer.

Proceedings of the Royal Society of Medicine·2010
Same author

Descriptive epidemiological features of cases of bovine spongiform encephalopathy born after July 31, 1996 in Great Britain.

The Veterinary record·2010
Same author

Penicillin prophylaxis in acute rheumatism.

Lancet (London, England)·2010
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Tumor-targeted enzyme strategies, including ADEPT, MDEPT, and AMIRACS, offer novel cancer treatment avenues. These methods utilize enzymes to activate prodrugs or inactivate rescue agents specifically at cancer sites, minimizing systemic toxicity.

Area of Science:

  • Biochemistry
  • Oncology
  • Drug Delivery

Background:

  • Tumor-specific enzyme activation strategies are crucial for targeted cancer therapy.
  • Antibody-Directed Enzyme Prodrug Therapy (ADEPT) and Macromolecule-Directed Enzyme Prodrug Therapy (MDEPT) utilize tumor-located enzymes to convert prodrugs into cytotoxic drugs.
  • Antimetabolite with Inactivation of Rescue Agent at Cancer Sites (AMIRACS) offers an alternative approach by inactivating protective agents.

Purpose of the Study:

  • To describe and evaluate two enzyme-based prodrug therapies (ADEPT, MDEPT) and one antimetabolite strategy (AMIRACS) for cancer treatment.
  • To explore the targeting capabilities of enzymes via antibodies and macromolecules, leveraging tumor vascular characteristics.
  • To discuss the management of systemic toxicity and the potential of exploiting tumor-specific or overexpressed enzymes.

Related Experiment Videos

Main Methods:

  • Targeting enzymes to tumors using antibody fragments (ADEPT) or polymeric macromolecules (MDEPT).
  • Utilizing the leaky tumor vasculature and poor lymphatic drainage for enzyme accumulation.
  • Developing prodrugs with high differential toxicity and extending the range of antimetabolites for AMIRACS.

Main Results:

  • Enzymes can be effectively targeted to tumor sites via ADEPT and MDEPT, with antibodies aiding clearance from normal tissues.
  • Human enzymes overexpressed in cancer cells present opportunities for targeted therapy.
  • Bacterial enzymes offer specificity but require immunogenicity management; prodrugs with short half-lives and high differential toxicity are advantageous.

Conclusions:

  • ADEPT, MDEPT, and AMIRACS represent promising strategies for localized cancer treatment by exploiting tumor-specific enzymes.
  • Careful management of enzyme activity in healthy tissues and prodrug/active drug toxicity is essential for therapeutic success.
  • Further development in enzyme targeting, prodrug design, and antimetabolite selection can enhance the efficacy of these enzyme-directed cancer therapies.